- cafead Jun 20, 2023 at 10:02: PM
via Immune checkpoint inhibitors haven’t had tons of success in stomach cancer. Now, Merck has added one failure to the mix.
Merck’s Keytruda didn’t move the needle in terms of preventing tumors from returning when used around surgery for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, the New Jersey pharma said Tuesday.
article source
Merck’s Keytruda didn’t move the needle in terms of preventing tumors from returning when used around surgery for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, the New Jersey pharma said Tuesday.
article source